[Form 4] Roivant Sciences Ltd. Insider Trading Activity

Rhea-AI Filing Summary

Matthew Gline, listed as Director and CEO of Roivant Sciences Ltd. (ROIV), reported a purchase of 3,315 common shares on 09/18/2025 at a weighted average price of $15.07 per share. After this transaction the filing shows Mr. Gline beneficially owns 17,287,081 common shares. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Gline.

Positive

• Reported acquisition of 3,315 common shares on 09/18/2025 at a weighted average price of $15.07
• Post-transaction beneficial ownership explicitly reported as 17,287,081 common shares
• Clear role disclosure: reporting person indicated as both Director and CEO

Negative

• None.

Insights

Financial Analyst

TL;DR: Insider purchase of 3,315 shares increases reported beneficial ownership to 17,287,081 shares; transaction reported on 09/18/2025.

The filing documents a routine non-derivative acquisition: 3,315 common shares acquired at a weighted average price of $15.07. The report explicitly states the post-transaction beneficial ownership total of 17,287,081 shares. No derivative transactions, dispositions, or additional price breakdowns beyond the weighted average are included, though the filer offers to provide per-price details on request.

Corporate Governance Expert

TL;DR: CEO and director reported a small open-market purchase and remains a substantial beneficial holder per the reported total shares.

The form identifies Matthew Gline as both an officer (CEO) and a director and discloses a single purchase code transaction (P) for 3,315 common shares. The signature block shows the filing was executed by an attorney-in-fact. The disclosure is limited to the transaction, price as a weighted average, and the updated beneficial ownership figure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Gline Matthew

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON X0 SW1H 0DB

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/18/2025		P		3,315	A	$15.07(1)	17,287,081	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range.

	By: /s/ Jo Chen, as Attorney-in-Fact for Matthew Gline	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ROIV insider Matthew Gline report on Form 4?

The Form 4 reports a purchase of 3,315 common shares on 09/18/2025 at a weighted average price of $15.07.

How many ROIV shares does Matthew Gline beneficially own after the transaction?

The filing shows Mr. Gline beneficially owns 17,287,081 common shares following the reported transaction.

What positions does the reporting person hold at Roivant Sciences (ROIV)?

The Form 4 indicates the reporting person is a Director and an Officer with the title CEO.

What price is reported for the shares purchased by the ROIV insider?

The price is reported as a weighted average of $15.07 per share; the filer offers to provide per-price details on request.

Who signed the Form 4 for Matthew Gline?

The form was signed by /s/ Jo Chen, as Attorney-in-Fact for Matthew Gline on 09/18/2025.